FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
30/01/2024
Voltar para busca
Dado oficial do USPTO
UNISTAC
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
30/01/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
06/08/2021
Data de registro
10/10/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
10/10/2023
Última transação
10/10/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
03
Localização do titular
KR
Examinador
DYER, ERIN
Unidade examinadora
L30
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
ONEGENE BIOTECHNOLOGY INC.
Representantes
Connie L. Ellerbach Fenwick & West LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical products for the treatment of infectious diseases; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the prevention of osteoporosis; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for the prevention of diseases of the endocrine system; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of hormonal disorders and the prevention of osteoporosis; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for the treatment of multiple sclerosis; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; pharmaceutical preparations for immunity adjustment; pharmaceutical preparations for the prevention of disorders of the immune system; pharmaceutical preparations for the prevention of diseases of the immune system; pharmaceutical preparations for regulating the immune system; pharmaceutical products for the treatment of viral diseases; pharmaceutical preparations for urogenital organs; pharmaceutical preparations for preventing and treating obesity; pharmaceutical products for the treatment of bone diseases; pharmaceutical preparations for wounds; pharmaceutical preparations for activating cellular function; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; cardiovascular treatment preparations; pharmaceutical preparations for the prevention of disorders of the nervous system; cardiovascular pharmaceuticals; pharmaceutical preparations for the treatment of cardiovascular disease; pharmaceutical preparations for treating malignant tumors; pharmaceutical preparations and compositions for the treatment and prevention of cancer; pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the prevention of inflammatory disorders; pharmaceutical preparations for the treatment of inflammatory diseases; antibacterial pharmaceuticals; pharmaceutical drugs being pharmaceutical preparations namelyfor the treatment of autoimmune diseasescardiovascular diseases and disorderscentral nervous system diseasesinflammatory diseases and disordersmetabolic diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disorders; synthetic peptides for pharmaceutical purposes namelyfor the treatment of autoimmune diseasescardiovascular diseases and disorderscentral nervous system diseasesinflammatory diseases and disordersmetabolic diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disorders; pharmaceutical compositions for the treatment of autoimmune diseasescardiovascular diseases and disorderscentral nervous system diseasesinflammatory diseases and disordersmetabolic diseases and disordersrespiratory diseases and disordersgastrointestinal diseases and disorders; clinical medical reagents; clinical diagnostic reagents for medicinal use; pharmaceutical preparations for the prevention of autoimmune disorders; pharmaceutical preparations for the prevention of autoimmune diseases; pharmaceutical preparations for the treatment of auto-immune diseases; pharmaceutical preparations for use in tissue transplantation; tissue-regenerative pharmaceutical preparations; pharmaceutical preparations for tumor treatment; stimulants for the central nervous system; pharmaceutical preparations for the treatment of central nervous system CNS diseases; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for the treatment of immune system related diseases and disorders; pharmaceutical products for treating respiratory diseases
Classe 42
Research and development of vaccines and medicines; research and development of technology for biotechnology; development of biotechnology; research relating to biotechnology; laboratory research in the field of biology; biological research services; development of new technologies in the field of biologics; drug discovery services; scientific research for medical purposes in the field of cancerous diseases; scientific research for medical purposes in the area of cancerous diseases; research in the field of pharmacogenetics; development of pharmaceutical preparations and medicines; laboratory research in the field of pharmaceuticals; testinginspection and research services in the fields of pharmaceuticalscosmetics and foodstuffs; pharmaceutical drug development services; pharmaceutical research and development; research relating to pharmaceuticals; scientific research in the field of pharmacy; medical laboratory services; research relating to new technologies for medical treatment; medical research laboratory services; scientific research for medical purposes in the area of cancerous diseases; research and development of new technologies for others in the field of amino acid for medical purpose; research and development of new technologies for others in the field of peptide for medical purposes; research and development of technology for medicinal chemical manufacturing; medicine research; scientific research relating to medical substances; medical research; scientific research relating to chemistry
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
10/01/2024
FIMP
FINAL DISPOSITION PROCESSED
10/01/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/01/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/10/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
10/10/2023
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
31/08/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
20/03/2023
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
17/03/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/03/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/03/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
21/02/2023
PUBO
PUBLISHED FOR OPPOSITION
21/02/2023
GPNX
NOTIFICATION PROCESSED BY IB
20/02/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/02/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
01/02/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/02/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
18/01/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
15/12/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
14/12/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
14/12/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
26/10/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
26/10/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
26/10/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
26/10/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
26/10/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
26/10/2022
RFNT
REFUSAL PROCESSED BY IB
05/07/2022
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
15/06/2022
RFRR
REFUSAL PROCESSED BY MPU
15/06/2022
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
13/05/2022
CNRT
NON-FINAL ACTION WRITTEN
12/05/2022
DOCK
ASSIGNED TO EXAMINER
06/05/2022
MAFR
APPLICATION FILING RECEIPT MAILED
09/10/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/10/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
30/09/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace UNISTAC ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.